Frontier Biosciences (688221.SH): FB7013 injection has obtained approval for drug clinical trials.

16:13 18/03/2026

Frontier Biotech (688221.SH) announced that the company recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving the company's FB7013 injection for clinical trials in the treatment of primary IgA nephropathy.

Frontier Biotech (688221.SH) announced that recently, the company has received approval from the National Medical Products Administration for a "Notice of Approval for Drug Clinical Trials", allowing the company's FB7013 injection to be used in clinical trials for the treatment of primary IgA nephropathy.

Director and General Manager Ge Jianghong of Huada Automotive Technology Corp.,Ltd (603358.SH) plans to increase holdings by 15 million to 30 million yuan.

FEG Holdings (01413) and its subsidiary have signed a memorandum of understanding with Rongyi Chaoyue for investment and development of health and wellness infrastructure.

YNBY INTL (00030) intends to conduct share repurchase on the open market.

Director and General Manager Ge Jianghong of Huada Automotive Technology Corp.,Ltd (603358.SH) plans to increase holdings by 15 million to 30 million yuan.

FEG Holdings (01413) and its subsidiary have signed a memorandum of understanding with Rongyi Chaoyue for investment and development of health and wellness infrastructure.

YNBY INTL (00030) intends to conduct share repurchase on the open market.